DUBLIN–(BUSINESS WIRE)–The “Osteogenesis
Imperfecta – Pipeline Review, H1 2019” drug pipelines has been
added to ResearchAndMarkets.com’s offering.
Osteogenesis Imperfecta – Pipeline Review, H1 2019, provides
comprehensive information on the therapeutics under development for
Osteogenesis Imperfecta (Genetic Disorders), complete with analysis by
stage of development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type. The guide covers the descriptive
pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases.
The Osteogenesis Imperfecta (Genetic Disorders) pipeline guide also
reviews key players involved in therapeutic development for Osteogenesis
Imperfecta and features dormant and discontinued projects. The guide
covers therapeutics under Development by
Companies/Universities/Institutes, the molecules developed by Companies
in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1,
1, 1, 2 and 1 respectively.
Osteogenesis Imperfecta (Genetic Disorders) pipeline guide helps in
identifying and tracking emerging players in the market and their
portfolios, enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage.
The pipeline guide provides a snapshot of the global therapeutic
landscape of Osteogenesis Imperfecta (Genetic Disorders).
The pipeline guide reviews pipeline therapeutics for Osteogenesis
Imperfecta (Genetic Disorders) by companies and universities/research
institutes based on information derived from company and
The pipeline guide covers pipeline products based on several stages of
development ranging from pre-registration till discovery and
The pipeline guide features descriptive drug profiles for the pipeline
products which comprise, product description, descriptive licensing
and collaboration details, R&D brief, MoA & other developmental
The pipeline guide reviews key companies involved in Osteogenesis
Imperfecta (Genetic Disorders) therapeutics and enlists all their
major and minor projects.
The pipeline guide evaluates Osteogenesis Imperfecta (Genetic
Disorders) therapeutics based on mechanism of action (MoA), drug
target, route of administration (RoA) and molecule type.
The pipeline guide encapsulates all the dormant and discontinued
The pipeline guide reviews latest news related to pipeline
therapeutics for Osteogenesis Imperfecta (Genetic Disorders)
Reasons to Buy
Procure strategically important competitor information, analysis, and
insights to formulate effective R&D strategies.
Recognize emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive advantage.
Find and recognize significant and varied types of therapeutics under
development for Osteogenesis Imperfecta (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
Develop tactical initiatives by understanding the focus areas of
Plan mergers and acquisitions meritoriously by identifying key players
and it’s most promising pipeline therapeutics.
Formulate corrective measures for pipeline projects by understanding
Osteogenesis Imperfecta (Genetic Disorders) pipeline depth and focus
of Indication therapeutics.
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
Adjust the therapeutic portfolio by recognizing discontinued projects
and understand from the know-how what drove them from pipeline.
Key Topics Covered:
- Report Coverage
- Osteogenesis Imperfecta – Overview
- Osteogenesis Imperfecta – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Osteogenesis Imperfecta – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
Osteogenesis Imperfecta – Companies Involved in Therapeutics Development
- Amgen Inc
- Bone Therapeutics SA
- Genzyme Corp
- Mereo Biopharma Group Plc
- SOM Biotech SL
Osteogenesis Imperfecta – Drug Profiles
- ALLOB – Drug Profile
- denosumab – Drug Profile
- Drug for Osteogenesis Imperfecta – Drug Profile
- fresolimumab – Drug Profile
- setrusumab – Drug Profile
Small Molecule to Agonize EP4 Receptor for Osteoporosis and
Osteogenesis Imperfecta – Drug Profile
Featured News & Press Releases
Oct 15, 2018: Completion of patient enrolment in phase 2b study of
BPS-804 for the treatment of osteogenesis imperfecta
Nov 13, 2017: Mereo Receives EMA PRIME Designation for BPS-804 to
Treat Osteogenesis Imperfecta
May 04, 2017: Initiation of BPS-804 potentially pivotal Phase 2b study
in patients with osteogenesis imperfecta, an orphan disease
Feb 20, 2017: Mereo BioPharma: BPS-804 accepted for EMA Adaptive
Jun 30, 2016: Mereo’s BPS-804 granted EU Orphan Drug status for
Mar 02, 2016: Mereo BPS-804 granted U.S. orphan drug status for
Oct 01, 2013: Bone Therapeutics receives clearance for ALLOB phase
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/lrklrv
Laura Wood, Senior Press Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900